Market Currents
Barron's sees the biotech sector enjoying its strongest start to a new year in a decade,...
-
Friday, January 20, 2012, 2:59 PM ETBarron's sees the biotech sector enjoying its strongest start to a new year in a decade, and this outperformance should continue for several reasons including P/E multiples and increasing M&A. The piece also discusses product ramp-ups at InterMune (ITMN), Human Genome Sciences (HGSI) and Regneron (REGN). (submitted by Bret Jensen)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
